Development of a cyclin-dependent kinase inhibitor devoid of ABC transporter-dependent drug resistance

BACKGROUND: Cyclin-dependent kinases (CDKs) control cell cycle progression, RNA transcription and apoptosis, making them attractive targets for anticancer drug development. Unfortunately, CDK inhibitors developed to date have demonstrated variable efficacy. METHODS: We generated drug-resistant cells...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Kaliszczak, M, Patel, H, Kroll, S H B, Carroll, L, Smith, G, Delaney, S, Heathcote, D A, Bondke, A, Fuchter, M J, Coombes, R C, Barrett, A G M, Ali, S, Aboagye, E O
Formato: Artigo
Idioma:Inglês
Publicado em: Nature Publishing Group 2013
Assuntos:
Translational Therapeutics
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3817326/
https://ncbi.nlm.nih.gov/pubmed/24071597
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/bjc.2013.584
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados